J. Zernicke

发表

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

E. Feist, H. Schulze-Koops, J. Listing, 2020, Annals of the Rheumatic Diseases.

Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity

A. Brachat, A. Martini, E. Feist, 2015, Pediatric Rheumatology.

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease

A. Brachat, A. Martini, E. Feist, 2015, Pediatric Rheumatology.

Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases

G. Burmester, V. Corman, C. Drosten, 2022, Annals of the Rheumatic Diseases.

A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren’s syndrome

G. Burmester, E. Feist, J. Callhoff, 2016, Clinical Rheumatology.

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination

L. Gieselmann, J. Klotsche, L. Sander, 2022, RMD Open.

Impaired Neutralization of SARS-CoV-2 Including Omicron Variants after COVID-19 mRNA Booster Immunization under Methotrexate Therapy.

L. Gieselmann, A. ten Hagen, J. Klotsche, 2022, medRxiv.

Association Among Rheumatoid Arthritis, Oral Hygiene, and Periodontitis

P. Schlattmann, T. Pischon, F. Buttgereit, 2008 .

Association among rheumatoid arthritis, oral hygiene, and periodontitis.

P. Schlattmann, T. Pischon, F. Buttgereit, 2008, Journal of periodontology.

Periodontal disease in patients with ankylosing spondylitis

P. Schlattmann, T. Pischon, F. Buttgereit, 2009, Annals of the rheumatic diseases.

Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non- to low-responders and B cell deficient rheumatic disease patients

J. Klotsche, G. Burmester, T. Alexander, 2023, Journal of Autoimmunity.

Distinct Effects of Interleukin-1β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still’s Disease and Active Articular Manifestation Responding to Canakinumab

D. Foell, E. Feist, G. Burmester, 2021, Journal of clinical medicine.

Peripheral blood mononuclear cells are hypomethylated in active rheumatoid arthritis and methylation correlates with disease activity.

Randall L. Lindquist, G. Burmester, S. Gay, 2020, Rheumatology.

A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis

G. Burmester, E. Feist, C. Kedor, 2016, BMC Musculoskeletal Disorders.

Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease

G. Burmester, V. Corman, J. Klotsche, 2022, RMD Open.

Pausing methotrexate improves immunogenicity of COVID-19 vaccination in patients with rheumatic diseases

A. ten Hagen, C. Drosten, J. Klotsche, 2021, medRxiv.

Response to: ‘Correspondence on ‘Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease’’ by Muraviov and Muraviova

E. Feist, C. Kedor, J. Zernicke, 2020, Annals of the Rheumatic Diseases.

Response to: ‘Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still’s disease’ by Ruscitti et al

E. Feist, J. Listing, C. Kedor, 2020, Annals of the Rheumatic Diseases.

THU0399 Effectiveness and Safety of Low-Dose Cyclosporine a in Patients with Primary Sjögren's Syndrome (PSS) with Articular Involvement – Results of a Pilot Study

J. Callhoff, C. Kedor, J. Zernicke, 2015 .

Performance of commercial SARS-CoV-2 wild-type and Omicron BA.1 antibody assays compared with pseudovirus neutralization tests

L. Gieselmann, J. Klotsche, G. Burmester, 2023, Journal of Clinical Virology.

THU0561 CANAKINUMAB FOR THE TREATMENT OF ADULT ONSET STILL‘S DISEASE TO ACHIEVE REDUCTION OF ARTHRITIC MANIFESTATION AT WEEK 12: AN INVESTIGATOR-INITIATED MULTI-CENTRE, PLACEBO-CONTROLLED STUDY (CONSIDER)

E. Feist, H. Schulze-Koops, J. Listing, 2019, Poster Presentations.

Canakinumab for Treatment of Adult Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): A Phase 2, Multi-Centre, Placebo-Controlled Study

E. Feist, H. Schulze-Koops, J. Listing, 2019, SSRN Electronic Journal.